The results of a recent study co-authored by C. David James, PhD, uncovered potential new targets for treating glioblastoma, a fatal brain tumor for which there is currently no cure.
New Northwestern Medicine research has shown that reprogrammed stem cells can be used to identify patients with cancer who are likely to experience a dangerous side effect of a common chemotherapy drug.
Lifang Hou, MD, PhD, chief of Cancer Epidemiology and Prevention in the Department of Preventive Medicine, has been named a member of a blue ribbon panel that will help inform the scientific direction of Vice President Joe Biden’s National Cancer Moonshot Initiative.
Two drugs known to improve survival for patients with metastatic renal cell carcinoma do not reduce the risk of cancer recurrence when administered after surgery, according to a recent clinical trial.
Research led by Northwestern Medicine scientist Daniel Foltz, ’01 PhD, sheds light on the assembly of centromeres, a region of the chromosome that helps ensure new cells have 46 chromosomes.
A recent clinical trial conducted by Northwestern Medicine investigator Seema Singhal, MD, showed that the drug daratumumab is a safe and effective treatment for patients with advanced multiple myeloma.
A new Northwestern Medicine study showed that deficient vitamin D blood levels in men can predict aggressive prostate cancer.
A phase III clinical trial tested the effectiveness of a combination of two drugs and found they may be an effective and safe treatment for patients with metastatic breast cancer.
By rotating special magnetic nanoparticles injected into brain tumors, a team of scientists led by Northwestern Medicine neurosurgical oncologist Maciej (Matt) Lesniak, MD, successfully damaged tumor cells in animal models.
Patients with cancer who watched personalized educational videos before their first visit with an oncologist were better equipped to consider participating in clinical trials, reports a paper co-authored by Northwestern Medicine investigator Al B. Benson, III, MD.